Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorKWINT, M.
dc.contributor.authorSTAM, B.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPROUST-LIMA, Cecile
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPHILIPPS, Viviane
dc.contributor.authorHOEKSTRA, T.
dc.contributor.authorAALBERSBERG, E.
dc.contributor.authorROSSI, M.
dc.contributor.authorSONKE, J. J.
dc.contributor.authorBELDERBOS, J.
dc.contributor.authorWALRAVEN, I.
dc.date.accessioned2021-02-01T14:42:31Z
dc.date.available2021-02-01T14:42:31Z
dc.date.issued2020
dc.identifier.issn0167-8140en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26080
dc.description.abstractEnIntroduction The aim of this study was to identify subgroups of locally advanced NSCLC patients with a distinct treatment response during concurrent chemoradiotherapy (CCRT). Subsequently, we investigated the association of subgroup membership with treatment outcomes. Methods 394 NSCLC-patients treated with CCRT between 2007 and 2013 were included. Gross Tumor Volume (GTV) during treatment was determined and relative GTV-volume change from the planning-CT was subsequently calculated. Latent Class Mixed Modeling (LCMM) was used to identify subgroups with distinct volume changes during CCRT. The association of subgroup membership with overall survival (OS), progression free survival (PFS) and local regional control (LRC) was assessed using cox regression analyses. Results Three subgroups of GTV-volume change during treatment were identified, with each subsequent subgroup showing a more profound reduction of GTV during treatment. No associations between subgroup membership and OS, PFS nor LRC were observed. Nonetheless, baseline GTV (HR1.42; 95%CI 1.06–1.91) was significantly associated with OS. Conclusions Three different subgroups of GTV-volume change during treatment were identified. Surprisingly, these subgroups did not differ in their risk of treatment outcomes. Only patients with a larger GTV at baseline had a significantly worse OS. Therefore, risk stratification at baseline might already be accurate in identifying the best treatment strategy for most patients.
dc.language.isoENen_US
dc.subjectBiostatistics
dc.title.enThe prognostic value of volumetric changes of the primary tumor measured on Cone Beam-CT during radiotherapy for concurrent chemoradiation in NSCLC patients
dc.title.alternativeRadiother Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.radonc.2020.02.002en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32114265en_US
bordeaux.journalRadiotherapy and Oncologyen_US
bordeaux.page44-51en_US
bordeaux.volume146en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03127578
hal.version1
hal.date.transferred2021-02-01T14:42:35Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Radiotherapy%20and%20Oncology&rft.date=2020&rft.volume=146&rft.spage=44-51&rft.epage=44-51&rft.eissn=0167-8140&rft.issn=0167-8140&rft.au=KWINT,%20M.&STAM,%20B.&PROUST-LIMA,%20Cecile&PHILIPPS,%20Viviane&HOEKSTRA,%20T.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée